Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:PLSE NASDAQ:SOLY NASDAQ:VERO NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.10+5.0%$2.10$0.76▼$2.73$79.42M1.4357,099 shs40,964 shsPLSEPulse Biosciences$14.52-3.8%$15.49$13.77▼$25.00$1.02B1.68147,206 shs438,302 shsSOLYSoliton$22.58$21.55$7.40▼$22.60$487.66M0.19347,827 shsN/AVEROVenus Concept$2.33+0.4%$2.45$2.10▼$14.50$3.32M0.0943,909 shs20,583 shsXAIRBeyond Air$2.43+7.5%$2.82$2.02▼$13.52$11.81M0.288.81 million shs512,744 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+5.00%+7.14%-10.64%+20.00%+68.00%PLSEPulse Biosciences-3.84%-3.90%-13.52%-7.93%-15.29%SOLYSoliton0.00%0.00%0.00%0.00%0.00%VEROVenus Concept+0.43%+2.19%-4.51%-7.17%-60.70%XAIRBeyond Air+7.52%+9.95%-0.82%-31.70%-68.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.10+5.0%$2.10$0.76▼$2.73$79.42M1.4357,099 shs40,964 shsPLSEPulse Biosciences$14.52-3.8%$15.49$13.77▼$25.00$1.02B1.68147,206 shs438,302 shsSOLYSoliton$22.58$21.55$7.40▼$22.60$487.66M0.19347,827 shsN/AVEROVenus Concept$2.33+0.4%$2.45$2.10▼$14.50$3.32M0.0943,909 shs20,583 shsXAIRBeyond Air$2.43+7.5%$2.82$2.02▼$13.52$11.81M0.288.81 million shs512,744 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+5.00%+7.14%-10.64%+20.00%+68.00%PLSEPulse Biosciences-3.84%-3.90%-13.52%-7.93%-15.29%SOLYSoliton0.00%0.00%0.00%0.00%0.00%VEROVenus Concept+0.43%+2.19%-4.51%-7.17%-60.70%XAIRBeyond Air+7.52%+9.95%-0.82%-31.70%-68.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/APLSEPulse Biosciences 3.00Buy$22.0051.52% UpsideSOLYSoliton 0.00N/AN/AN/AVEROVenus Concept 0.00N/AN/AN/AXAIRBeyond Air 3.50Strong Buy$11.00352.67% UpsideCurrent Analyst Ratings BreakdownLatest SOLY, PLSE, XAIR, VERO, and APYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/13/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.007/17/2025XAIRBeyond AirD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$22.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$46.51M1.71N/AN/A$0.38 per share5.53PLSEPulse Biosciences$700K1,395.99N/AN/A$1.87 per share7.76SOLYSolitonN/AN/AN/AN/A$1.46 per shareN/AVEROVenus Concept$60.11M0.06N/AN/A$4.30 per share0.54XAIRBeyond Air$4.78M2.66N/AN/A$3.32 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)PLSEPulse Biosciences-$53.58M-$1.05N/A∞N/AN/A-63.19%-54.98%10/29/2025 (Estimated)SOLYSoliton-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/AVEROVenus Concept-$47M-$50.78N/A∞N/A-68.77%-871.77%-61.92%11/13/2025 (Estimated)XAIRBeyond Air-$46.62M-$11.93N/AN/AN/A-880.72%-232.61%-115.92%11/10/2025 (Estimated)Latest SOLY, PLSE, XAIR, VERO, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VEROVenus Concept-$9.72-$8.03+$1.69-$8.03$14.01 million$15.69 million8/12/2025Q2 2025PLSEPulse Biosciences-$0.26-$0.28-$0.02-$0.28$0.50 millionN/A8/12/2025Q1 2026XAIRBeyond Air-$1.50-$1.53-$0.03-$1.53$1.75 million$1.76 million8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 million6/17/2025Q4 2025XAIRBeyond Air-$2.80-$1.80+$1.00-$0.09$1.39 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ASOLYSolitonN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95PLSEPulse BiosciencesN/A12.0512.04SOLYSolitonN/A5.475.37VEROVenus Concept5.721.100.71XAIRBeyond Air0.923.242.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%PLSEPulse Biosciences76.95%SOLYSoliton35.11%VEROVenus Concept87.41%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%PLSEPulse Biosciences74.60%SOLYSoliton12.00%VEROVenus Concept28.04%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionablePLSEPulse Biosciences14067.30 million17.09 millionOptionableSOLYSoliton1421.60 million19.01 millionNot OptionableVEROVenus Concept4101.42 million1.03 millionNot OptionableXAIRBeyond Air705.23 million4.21 millionOptionableSOLY, PLSE, XAIR, VERO, and APYX HeadlinesRecent News About These CompaniesBeyond Air Announces New Warrant AgreementSeptember 11 at 11:27 PM | msn.comBeyond Air, Inc. Announces Exercise of Warrants to Raise $3.25 Million for Clinical Programs and OperationsSeptember 8, 2025 | quiverquant.comQBeyond Air Announces Exercise of Warrants for $3.25 Million of Gross ProceedsSeptember 8, 2025 | globenewswire.comNeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in AdultsSeptember 8, 2025 | markets.businessinsider.comBeyond Air subsidiary granted orphan designation for malignant glioma treatmentSeptember 3, 2025 | msn.comBeyond Air, Inc. CEO Steve Lisi to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comBeyond Air, Inc. Expands Global LungFit® PH Distribution Network to 34 CountriesAugust 20, 2025 | quiverquant.comQBeyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanAugust 20, 2025 | globenewswire.comBeyond Air price target lowered to $5 from $20 at Piper SandlerAugust 14, 2025 | msn.comBeyond Air’s Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Call TranscriptAugust 13, 2025 | msn.comBeyond Air Reports Strong Revenue Growth in Q1 2026August 13, 2025 | msn.comBeyond Air reports Q1 EPS ($1.53) vs. ($5.32) last yearAugust 12, 2025 | msn.comBeyond Air, Inc. (XAIR) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comBeyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue EstimatesAugust 12, 2025 | zacks.comBeyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To ExpectAugust 12, 2025 | finance.yahoo.comBeyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and WebcastJuly 25, 2025 | globenewswire.comBeyond Air stock surges after securing Premier group purchasing dealJuly 22, 2025 | in.investing.comBeyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.July 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSOLY, PLSE, XAIR, VERO, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$2.10 +0.10 (+5.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.12 +0.02 (+1.19%) As of 09/12/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Pulse Biosciences NASDAQ:PLSE$14.52 -0.58 (-3.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.54 +0.02 (+0.14%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Soliton NASDAQ:SOLYSoliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.Venus Concept NASDAQ:VERO$2.33 +0.01 (+0.43%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.33 0.00 (0.00%) As of 09/12/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.Beyond Air NASDAQ:XAIR$2.43 +0.17 (+7.52%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.42 -0.01 (-0.21%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
